“`html
The average one-year price target for Editas Medicine (NasdaqGS:EDIT) has risen to $4.95 per share, a 22.78% increase from the previous estimate of $4.03 on November 14, 2025. This new target represents a 104.42% increase from the last reported closing price of $2.42 per share, with analyst targets ranging from a low of $1.01 to a high of $13.65 per share.
Currently, 328 funds report positions in Editas Medicine, a decrease of 0.91% over the last quarter. Institutional ownership has increased by 6.78% to 50,665K shares, with an average portfolio weight of 0.02%. The put/call ratio stands at 0.09, indicating a bullish sentiment.
Significant shareholders include Vanguard Total Stock Market Index Fund (2,592K shares, 2.66% ownership, stable), iShares Russell 2000 ETF (2,117K shares, 2.17% ownership, down 4.56%), Nuveen (2,092K shares, 2.14% ownership, up 54.59%), and Geode Capital Management (2,040K shares, 2.09% ownership, up 3.72%).
“`
